Search results for " review"
Article
Biopharmaceutical Market in Asia: Q&A with Günter Jagschies, Strategic Customer Relations Leader, Cytiva
Specific topics will be the review of health challenges in Asia and future approaches to address them, creative technology solutions, facility and regulatory aspects, as well as vaccines and plasma de…
Article
Process Development: What May Lie Ahead in 2018?
Readers were very interested to learn how to prevent bioburden incidents in this article written by a former FDA BLA reviewer and inspector. Also hot was a second piece on protecting against microbiol…
Article
What's in Your SOP?
This activity might be acceptable on the condition that the purchased SOP is reviewed and the appropriate changes be made to reflect the actual operations of the company who purchased the SOP. Failure…
Article
Bioburden Entry Points in Downstream Processing
Anastasia Lolas, former FDA Biologics License Application (BLA) reviewer and inspector focusing on microbiology, shares her expert tips in this blog.
Article
Transformative Medicines Challenge FDA and Manufacturers
FDA published a draft guidance in February 2016 on human factors studies for combination products (2) and is reviewing comments to finalize the policy.
As FDA and industry continue to scope ou…
Article
Prepare for an FDA Bioburden Inspection
Anastasia Lolas, former FDA Biologics License Application (BLA) reviewer and inspector focusing on microbiology, shares her expert tips.
Read blog here
Article
Contract Manufacturing Through the Years
In light of Pharmaceutical Technology’s 40th anniversary, it is appropriate to review the CDMO industry’s evolution and outlook.
Early days
Phase one of the CDMO industry includes the y…
Article
N-Glycan Analysis of Biotherapeutic Proteins
In this article, the biological effects of N-glycosylation on protein biologics are reviewed—together with the range of analytical techniques that are used to elucidate the N-glycosylation characteris…
Article
Managing Residual Impurities During Downstream Processing
…hnology that provide enhanced means of monitoring--have, however, been key drivers for the continued review and optimization of guidelines for the manufacture of biologic drugs, according to Ashleigh…
Article
Automating Bioprocesses
Companies have been moving towards CPV rather than annual product reviews. Requirements are emerging, particularly for biopharmaceuticals, to provide CPV across all manufacturing locations for a produ…